Oxcarbazepine (Oxtellar XR) vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
Reported efficacy
Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)
Result source: NCT00908349
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.
The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.
Reported efficacy
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)
Result source: NCT00334958
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Oxcarbazepine (Oxtellar XR) | Rufinamide |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not reported |
| 50% responder rate | 50% vs 34%+16 vs placeboNCT007726031 other result
| —Not reported |
| Seizure freedom | —Not reported | —Not reported |
Seizure frequency, % change
- Oxcarbazepine (Oxtellar XR)
- —Not reported
- Rufinamide
- —Not reported
50% responder rate
- Oxcarbazepine (Oxtellar XR)
- 50% vs 34%+16 vs placeboNCT00772603
1 other result
- 44% vs 34% NCT00772603
- Rufinamide
- —Not reported
Seizure freedom
- Oxcarbazepine (Oxtellar XR)
- —Not reported
- Rufinamide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Oxcarbazepine (Oxtellar XR): 4 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Oxcarbazepine (Oxtellar XR) | Rufinamide |
|---|---|---|
| Dropout rate | 42.3%2400 mg/daya NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results32.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 16.4% NCT00908349 · Phase 3 · monotherapy | 21%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 24.1% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 30.1%2400 mg/daya NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results14.8%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 4.7% NCT00908349 · Phase 3 · monotherapy | 15.3%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 12% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 7.4% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 8.1%2400 mg/daya NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results5.7%1200 mg/day NCT00772603 · Phase 3 · Epilepsy · phase 3 8.4% NCT00908349 · Phase 3 · monotherapy | 3.4%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results3.4% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 16.7% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 2400 mg/daya dizziness 40.7% (placebo 14.9%) headache 15.4% (placebo 7.4%) vomiting 15.4% (placebo 9.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 show 2 more results1200 mg/day dizziness 19.7% (placebo 14.9%) somnolence 11.5% (placebo 9.1%) diplopia 9.8% (placebo 4.1%) NCT00772603 · Phase 3 · Epilepsy · phase 3 | b dizziness 26.7% (placebo 8.3%) headache 16.5% (placebo 12.8%) fatigue 15.3% (placebo 10%) NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more resultsnasopharyngitis 31% (placebo 30%) status epilepticus 27.6% (placebo 16.7%) decreased appetite 20.7% (placebo 6.7%) NCT01146951 · Phase 3 · monotherapy upper respiratory tract infection 28% vomiting 28% somnolence 20% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 nasopharyngitis 48.1% status epilepticus 40.7% somnolence 25.9% NCT01151540 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Oxcarbazepine (Oxtellar XR)
show 1 more result
show 1 more result
show 1 more result
Rufinamide
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxcarbazepine (Oxtellar XR)'s landscape · Rufinamide's landscape